FDA and the safe and appropriate antibiotic use of fluoroquinolones

The Lancet Infectious Diseases

Volumn 16, Issue 3, 2016, Pages e11-e12

  Tillotson, Glenn S ^a  

^a GST Micro LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADVERSE OUTCOME; ALLERGY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HUMAN; INFECTION; MUSCULOSKELETAL DISEASE; NOTE; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; BACTERIAL INFECTIONS; BRONCHITIS, CHRONIC; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; LEGISLATION AND JURISPRUDENCE; RISK FACTOR; SINUSITIS; STANDARDS; UNITED STATES; URINARY TRACT INFECTIONS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BRONCHITIS, CHRONIC; DRUG UTILIZATION; FLUOROQUINOLONES; HUMANS; RISK FACTORS; SINUSITIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; URINARY TRACT INFECTIONS;

EID: 84959189990     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)00051-7     Document Type: Note

References (1)

1. Joint Meeting of the Antimicrobial Drugs Advisory Committee Meeting (AMDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) US Food and Drug Administration, (accessed Jan 28, 2016). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm470444.pdf.